← ANALYST RATINGS · TIPRANKS
LivaNova (LIVN): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $89.60, the highest $105, the lowest $75.00. The average is +15.5% from the last price of $77.58.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $105 | Buy | +35.3% | Initiated | 07.10.26on TipRanks 03:55 | +1.6%next day +0.4% · 5 days +1.2% | ↗ |
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $87.00 → $90.00+3.4% | Buy | +16.0% | Reiterated | 02.09.26on TipRanks 06:50 | +2.4%next day −2.5% · 5 days −4.2% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | — | Buy | — | Reiterated | 21.08.26on TipRanks 07:25 | +0.3%next day −0.3% · 5 days +1.5% | ↗ |
| Keith Hinton★★★★★★★★★★#7123 · hits 80% · avg +7.0% | Freedom Capital Markets | $81.00 → $75.00−7.4% | Hold | −3.3% | Reiterated | 20.08.26on TipRanks Sep 27 05:10 | −2.4%next day +0.3% · 5 days +1.2% | ↗ |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $98.00 → $89.00−9.2% | Buy | +14.7% | Upgrade | 20.08.26on TipRanks 01:05 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $88.00 → $97.00+10.2% | Buy | +25.0% | Reiterated | 05.08.26on TipRanks 17:05 | — | |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $80.00 → $85.00+6.2% | Buy | +9.6% | Reiterated | 05.08.26on TipRanks 14:05 | −8.2%next day −2.9% · 5 days +3.0% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $81.00 → $93.00+14.8% | Buy | +19.9% | Reiterated | 05.08.26on TipRanks 13:21 | −8.2%next day −2.9% · 5 days +3.0% | ↗ |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $89.00 → $99.00+11.2% | Buy | +27.6% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $82.00 → $90.00+9.8% | Hold | +16.0% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $89.00 → $95.00+6.7% | Buy | +22.5% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $87.00 → $94.00+8.0% | Buy | +21.2% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| Brett Fishbin★★★★★★★★★★#10514 · hits 45% · avg −3.0% | KeyBanc | $83.00 → $92.00+10.8% | Buy | +18.6% | Assigned | 22.06.26on TipRanks 02:30 | +0.6%next day +1.4% · 5 days +6.0% | ↗ |
| David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% | Robert W. Baird | $78.00 → $76.00−2.6% | Buy | −2.0% | Reiterated | 07.05.26on TipRanks 07:25 | +7.3%next day +0.5% · 5 days −1.2% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $70.00 → $72.00+2.9% | Hold | −7.2% | Reiterated | 06.05.26on TipRanks May 7 07:15 | +13.7%next day +7.3% · 5 days +8.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering LivaNova
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $85.75 at a price of $76.50 (+12.1%); now: $89.60 at $77.58 (+15.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 5 | 6 | 6 | 6 | 5 | 5 |
| Hold | 2 | 3 | 3 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.06 (from $1.02 to $1.13). Last quarter: $1.26.
Sales
Next quarter’s sales estimate — $381M (from $378M to $386M). Last quarter: $391M.
Best top-analyst consensus in the sector · Healthcare
About LivaNova
- CEO: Vladimir A. Makatsaria
- Employees: 3,300
- 5220 Valiant Court, Gloucester, GL, GL3 4FE, GB
- www.livanova.com
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Data from the stock’s TipRanks forecast page, read 81 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗